SATURDAY, Dec. 4 (HealthDay News) -- A new anti-clotting pill,
rivaroxaban (Xarelto), may be an effective, convenient and safer
treatment for patients coping with deep-vein thrombosis (DVT), a
pair of new studies indicate.
According to the research, published online Dec. 4 in the
New England Journal of Medicine, the drug could offer a new option for these potentially life-threatening clots, which most typically form in the lower leg or thigh.
The findings are also slated for presentation Saturday at the
annual meeting of the American Society of Hematology (ASH), in
"These study outcomes may possibly change the way that patients with DVT are treated," study author Dr. Harry R. Buller, a professor of medicine at the Academic Medical Center at the University of Amsterdam, said in an ASH news release. "This new treatment regimen of oral rivaroxaban can potentially make blood clot therapy easier than the current standard treatment for both the patient and the physician, with a single-drug and simple fixed-dose approach."
Another heart expert agreed.
"Rivaroxiban is at least as effective as the older drug [warfarin] and seems safer. It is also far easier to use since it does not require blood testing to adjust the dose," said cardiologist Dr. Alan Kadish, currently president of Touro College in New York City.
The study was funded in part by Bayer Schering Pharma, which
markets rivaroxaban outside the United States. Funding also came
from Ortho-McNeil, which will market the drug in the United States
should it gain U.S. Food and Drug Administration approval. In March
2009, an FDA advisory panel recommended the drug be approved, but
agency review is ongoing pending further study.
The authors note that upwards of 2 million Americans experience
a DVT each year. These leg clots -- sometimes called "economy
flight syndrome" since they've been associated with the
immobilization of long flights -- can migrate to the lungs to form
potentially deadly pulmonary embolisms.
The current standard of care typically involves treatment with
relatively well-known anti-coagulant medications, such as the oral
medication warfarin (Coumadin) and/or the injected medication
While effective, in some patients these drugs can prompt
unstable responses, as well as problematic interactions with other
medications. For warfarin in particular, the potential also exists
for the development of severe and life-threatening bleeding. Use of
these drugs, therefore, requires intense and continuous
The search for a safer and easier to administer treatment option
led Buller's team to analyze two sets of data: One that pitted
rivaroxaban against the standard anti-clotting drug enoxaparin (a
heparin-type medication), and the second which compared rivaroxaban
with a placebo.
In the first instance, about 1,700 DVT patients were given
rivaroxaban, while a similar number received enoxaparin, for a
period of up to a year. In the second investigation, about 600 DVT
patients who had completed at least six months of the first trial
(on either medication) were randomly chosen to take rivaroxaban,
while a similar number of patients were given a placebo.
The authors observed that fewer cases of clotting took place
among the rivaroxaban group compared with those taking enoxaparin
(2.1 percent vs. 3 percent, respectively). Major bleeding was also
slightly less common among the former than the latter.
The new medication also significantly outperformed the placebo,
with just over 1 percent of rivaroxaban patients experiencing
clotting problems compared with more than 7 percent in the placebo
Although bleeding issues were more prevalent among rivaroxaban
patients than among those taking a placebo, the research team
determined that the new treatment option is both safe and effective
for the treatment of DVT.
Dr. Murray A. Mittleman, director of the Cardiovascular
Epidemiology Research Unit at Beth Israel Deaconess Medical Center
at Harvard Medical School in Boston, said finding alternate
treatments for DVT could be an "important advancement," even though
rivaroxaban is likely to be a more expensive option.
"The problem with current treatments is not cost," he noted, "in the sense that warfarin, for example, has been around for a very long time and is very cheap. It's more a question of the considerable complications that come with current treatments, which means they require sometimes cumbersome and frequent monitoring, as well as dosage adjustments."
Kadish agreed. "While the cost of rivaroxiban is significant,
the absence of monitoring costs, reduced time away from work [since
blood test are not required] and the lower bleeding rate all serve
to mitigate the cost differential relative to warfarin," he
"Also, DVT affects a broad age range of patients," Mittleman noted. "And that means that the risk for bleeding with current treatments can impact the lifestyles of young active people who are often advised to avoid activities that might prompt complications. So, it's a quality-of-life issue as well. So absolutely, a new, good treatment that would be safer and at least as effective would be very useful."
There's more on DVTs at the
U.S. National Heart, Lung, and Blood
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.